Histamine News and Research

RSS

Histamine is a biogenic amine chemical involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.

Research into hay fever and temperature of the nose rises helps determine how reliable and effective anti-allergic agents are

In an attack of hay fever, the temperature of the nose rises. Effective medication prevents this too. An infrared camera provides non-contact images of the changes. Researchers can use these images to determine how reliable and effective anti-allergic agents are.

8 Jul 2004

Genes that allow nerve cells to communicate may have come from bacteria eons ago

Some of the genes that allow nerve cells and some other types of cells to send elaborate chemical messages to each other appear to have been transferred to animals or their immediate ancestors from bacteria eons ago.

2 Jun 2004

Brain cells containing the chemical histamine are critical for waking

A study by scientists with the Veterans Affairs' Neurobiology Research Laboratory and UCLA Neuropsychiatric Institute shows that brain cells containing the chemical histamine are critical for waking.

27 May 2004

Phase 3 trial of Ceplene in acute myeloid leukemia meets primary trial endpoint

Maxim Pharmaceuticals has announced the results of an international Phase 3 clinical trial testing the combination of Ceplene (TM) plus interleukin-2 (IL-2) in 320 patients with acute myeloid leukemia (AML) in complete remission.

12 May 2004

Preclinical data on Histamine's ability to prevent liver damage

These new results demonstrate the ability of histamine to prevent LPS-induced liver injury in a rodent model by showing efficacy when delivered in a manner mimicking oral administration.

19 Apr 2004

FDA approves advanced malignant melanoma drug

Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA).

14 Apr 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.

22 Mar 2004